Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial
- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -
- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -
Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.
Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.
Please subscribe to receive our latest news